MAY 14 2026
AstraZeneca — Fasenra (benralizumab) $AZN
for Hypereosinophilic Syndrome
FDA approved AstraZeneca's Fasenra for adult and pediatric patients aged 12+ with hypereosinophilic syndrome without an identifiable non-hematologic cause.
About
Hypereosinophilic syndrome is a condition where high levels of white blood cells called eosinophils persist in the blood for months, which can damage the heart, nerves, or bone marrow. Fasenra (benralizumab) is an antibody that binds to a receptor on eosinophils, prompting the body's immune system to rapidly remove these cells. By depleting eosinophils, this drug may reduce the tissue damage that drives the serious complications of the disease.
Pivotal trial
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Fasenra
- Fasenra® (benralizumab) now approved in Canada for hypereosinophilic syndrome - PR Newswire Canada
- AstraZeneca secures label expansion for asthma blockbuster Fasenra in India - ETPharma.com
- CDSCO Approves AstraZeneca's Fasenra for Hypereosinophilic Syndrome in India - Medical Dialogues
- Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication - tradingview.com
- AstraZeneca Pharma India gets CDSCO nod for additional Fasenra indication - business-standard.com